dPCR Case Study

Overview


dPCR-Case-Study.png

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring your adoptive cell therapy (ACT) meets safety regulations relating to VCN and RCL/RCR levels, even in lymphodepleted samples. By detecting the smallest changes in VCN, dPCR is our method of choice for pharmacokinetics (PK) assays. As for replication competent viruses, they can easily be detected using qPCR, ensuring patient safety and regulatory compliance. 

This content is provided by CellCarta, and any views and opinions expressed do not necessarily reflect those of Outsourcing-Pharma.com

Download Now


Related Resources

Partner with Experts in Precision Medicine

Partner with Experts in Precision Medicine

Content provided by CellCarta

Product Brochure

At CellCarta, we’re dedicated to working with our partners to further the limitless potential of precision medicine. Our broad technology offering is designed to address specific therapeutic development requirements and provide the most highly customized...

Supplier Info Centre

CellCarta.jpg

For more product information visit CellCarta.